Gabriel T Sayer
Overview
Explore the profile of Gabriel T Sayer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cali F, Pinsino A, Ladanyi A, Mondellini G, Lee C, Sayer G, et al.
J Card Fail
. 2025 Feb;
PMID: 40021045
No abstract available.
2.
Uriel N, Fried J, Yunis A, Clerkin K, Lotan D, Elad B, et al.
J Card Fail
. 2025 Feb;
PMID: 39954844
No abstract available.
3.
Elad B, Lee C, Rahman A, Rzechorzek W, Defilippis E, Lotan D, et al.
Artif Organs
. 2025 Jan;
PMID: 39835590
Background: GLP-1 RAs improve cardiometabolic outcomes in obese, diabetic, and heart failure patients. Data on the safety and efficacy of GLP-1 RA in advanced heart failure with durable LVAD is...
4.
Moeller C, Oren D, Fernandez Valledor A, Rubinstein G, Defilippis E, Rahman S, et al.
Circ Heart Fail
. 2024 Dec;
18(1):e011756.
PMID: 39655433
Background: Cardiac allograft vasculopathy (CAV) leads to impaired myocardial blood flow (MBF), increasing the risk of cardiovascular death or retransplant among heart transplantation (HT) recipients. Data on elevation in donor-derived...
5.
Kaneyuki D, Patel K, Vinogradsky A, Rajesh K, Hynds M, Kurlansky P, et al.
ASAIO J
. 2024 Nov;
PMID: 39531597
Prosthetic valve-related morbidity and mortality in patients with left ventricular assist devices (LVADs) remain unclear. We retrospectively reviewed patients who received a HeartMate II or 3 LVAD at our center...
6.
Harris E, Prasad N, Skoll D, Kumar S, Fried J, Topkara V, et al.
Clin Transplant
. 2024 Oct;
38(10):e70009.
PMID: 39436145
Cardiac allograft vasculopathy (CAV) is a major cause of morbidity and mortality following heart transplantation (HT). Prior studies identified distinct CAV trajectories in the early post-HT period with unique predictors,...
7.
Feng I, Kurlansky P, Powley T, Hynds M, Yang C, Eisenberger A, et al.
Artif Organs
. 2024 Oct;
49(3):497-507.
PMID: 39377154
Background: No clear guidelines exist for perioperative anticoagulation management after durable left ventricular assist device insertion. In this study, we sought to compare outcomes between anti-factor Xa (FXa) and activated...
8.
Mondellini G, Vinogradsky A, Kirschner M, Pinsino A, Ladanyi A, Kurlansky P, et al.
ASAIO J
. 2024 Sep;
PMID: 39326050
No abstract available.
9.
Moroi M, Patel K, Rajesh K, Lin A, Wang P, Wang C, et al.
J Thorac Cardiovasc Surg
. 2024 Sep;
PMID: 39260600
Objective: Donation after circulatory death heart transplantation potentially increases donor allografts, especially for patients with lower listing status. We assessed the outcomes of donation after circulatory death heart transplantation in...
10.
Fernandez Valledor A, Moeller C, Rubinstein G, Oren D, Rahman S, Baranowska J, et al.
Expert Rev Med Devices
. 2024 Aug;
21(9):829-840.
PMID: 39169616
Introduction: The scarcity of donors coupled with the improvements in left ventricular assist devices (LVAD) technology has led to the use of LVAD as a bridge to transplantation (BTT). Areas...